3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
13
Breast Neoplasms
11
Carcinoma, Transitional Cell
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasm Metastasis
4
Lung Neoplasms
3
Small Cell Lung Carcinoma
2
Urothelial Bladder Carcinoma
1
Salivary Gland Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Localized Muscle Invasive Bladder Urothelial Carcinoma
1
Liver Failure
1
HRD Cancer
1
Glioblastoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Carcinoma, Small Cell
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
28
Paclitaxel
24
Carboplatin
19
Bevacizumab
14
Specimen Handling
13
Magnetic Resonance Spectroscopy
10
Doxorubicin
8
Cisplatin
8
Biopsy
8
olaparib
7
lenvatinib
7
Taxes
7
Letrozole
7
Megestrol Acetate
6
Fulvestrant
6
durvalumab
5
dostarlimab
5
Nivolumab
5
Medroxyprogesterone Acetate
5
Gemcitabine
5
trastuzumab deruxtecan
4
abemaciclib
4
X-Rays
4
Trastuzumab
4
Tirzepatide
4
Progestins
4
Oxaliplatin
4
Immunoglobulin G
4
Fluorouracil
4
Docetaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
sacituzumab govitecan
×
90 days
×
Clear all
No trials found.